Akebia Therapeutics (AKBA) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $166.4 million.
- Akebia Therapeutics' Cash & Current Investments rose 38926.78% to $166.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.4 million, marking a year-over-year increase of 38926.78%. This contributed to the annual value of $51.9 million for FY2024, which is 2083.87% up from last year.
- Akebia Therapeutics' Cash & Current Investments amounted to $166.4 million in Q3 2025, which was up 38926.78% from $137.3 million recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Cash & Current Investments registered a high of $252.8 million during Q1 2021, and its lowest value of $34.0 million during Q3 2024.
- For the 5-year period, Akebia Therapeutics' Cash & Current Investments averaged around $115.5 million, with its median value being $113.4 million (2025).
- Per our database at Business Quant, Akebia Therapeutics' Cash & Current Investments plummeted by 6786.67% in 2023 and then skyrocketed by 38926.78% in 2025.
- Quarter analysis of 5 years shows Akebia Therapeutics' Cash & Current Investments stood at $149.8 million in 2021, then tumbled by 39.61% to $90.5 million in 2022, then crashed by 52.55% to $42.9 million in 2023, then rose by 20.84% to $51.9 million in 2024, then skyrocketed by 220.89% to $166.4 million in 2025.
- Its Cash & Current Investments stands at $166.4 million for Q3 2025, versus $137.3 million for Q2 2025 and $113.4 million for Q1 2025.